Physician profile

Michael Howard Porter

Oral and Maxillofacial Surgery · Charleston, SC

NPI 1578890620

$4,229.20

in general payments reported to CMS, 2019-2025

5 companies · $400 in 2025

The $400 reported for 2025 was more than what a typical Oral and Maxillofacial Surgery provider received nationally (typical 2025 total: $150).

See the full distribution for Oral and Maxillofacial Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,081.90
Entertainment$85.00
Gift$48.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Straumann USA LLC $3,635.60 2020-2025
Dentsply Sirona INC $345.26 2019-2021
Nobel Biocare USA $116.54 2019
Stryker Corporation $113.22 2019
Implant Direct Sybron International LLC $18.58 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Howard Porter

$4,229.20

in general payments reported 2019-2025

Years
2019-2025
Top company
Straumann USA LLC
Context
The $400 reported for 2025 was more than what a typical Oral and Maxillofacial Surgery provider received nationally (typical 2025 total: $150).

https://glasscript.com/doctor/1313212/michael-howard-porter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.